An observational study in Glaucoma, sponsored by University of Kentucky. Terminated at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-04-24.
Sponsored by University of Kentucky · Observational
Primary objective is to evaluate the effect of selective laser trabeculoplasty (SLT) on the diurnal intraocular pressure variation in open-angle glaucoma patients (OAG).
This is a prospective observational study of OAG patients undergoing selective laser trabeculoplasty at the University of Kentucky Chandler Medical Center. The patients will be recruited over 12 months. Study will include 3 visits: pre-laser visit, visit for laser treatment and post-laser visit. All visits will occur within a 3-month period.
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's enrollment of 30 is below the median of 103 across 454 observational studies indexed under Glaucoma.
Browse Glaucoma studies →University of Kentucky is the lead sponsor of 68 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Thirty patients, between the ages of 40 and 80, of either gender, from all ethnic backgrounds will be recruited in this study.
Exclusion Criteria:
Subjects with POAG and on medical treatment who are undergoing SLT
Procedure: Surgery · Procedure: Selective Laser Trabeculoplasty
Glaucoma laser treatment
Selective Laser Trabeculoplasty for glaucoma
Also known as: Selective Laser Trabeculoplasty
Glaucoma Treatment
Also known as: SLT
To evaluate the effect of selective laser trabeculoplasty on the diurnal intraocular pressure variation in OAG patients.
Time frame: Three years
This study is terminated, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Kentucky